Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab

Published:2019-06-03 Issue:6 Volume:54 Page:726-732
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Ylisaukko-Oja Tero¹²,Torvinen Saku³,Ventola Hanna¹,Schmidt Saku³,Herrala Sauli¹,Kononoff Jenni¹,Voutilainen Markku⁴⁵

Affiliation:

1. MedEngine Oy, Helsinki, Finland;

2. Center for Life Course Health Research, University of Oulu, Oulu, Finland;

3. Takeda Oy, Helsinki, Finland;

4. Division of Medicine, Turku University Hospital, Turku, Finland;

5. Department of Medicine, University of Turku, Turku, Finland

Funder

Takeda Oy

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2019.1627579

Reference31 articles.

1. Inflammatory Bowel Disease

2. The global burden of IBD: from 2015 to 2025

3. Crohn's disease

4. Ulcerative colitis

5. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn's disease patients treated with biologics;Digestive and Liver Disease;2023-09

2. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis;Advances in Therapy;2023-03-31

3. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis;Expert Opinion on Pharmacotherapy;2022-05-09

4. The Magnitude of Crohn’s Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review;Inflammatory Bowel Diseases;2022-02-18

5. Dose–escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice;Scandinavian Journal of Gastroenterology;2021-12-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3